Aslan Pharmaceuticals Ltd ADR
(ASLN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | N/A | -44,087 | N/A | -20,933 | N/A |
| Depreciation Amortization | N/A | 349 | N/A | 181 | N/A |
| Accounts receivable | N/A | N/A | N/A | -12,000 | N/A |
| Accounts payable and accrued liabilities | N/A | -4,866 | N/A | -6,480 | N/A |
| Other Working Capital | N/A | -2,952 | N/A | -16,799 | N/A |
| Other Operating Activity | 0 | 4,917 | 0 | 18,701 | 0 |
| Operating Cash Flow | $N/A | $-46,639 | $N/A | $-37,329 | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -11 | N/A | -9 | N/A |
| Other Investing Activity | 0 | 279 | 0 | 279 | 0 |
| Investing Cash Flow | $N/A | $269 | $N/A | $270 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | -12,000 | N/A | N/A | N/A |
| Common Stock Issued | N/A | 19,656 | N/A | 17,830 | N/A |
| Other Financing Activity | 0 | 3,064 | 0 | 3,272 | 0 |
| Financing Cash Flow | $N/A | $10,721 | $N/A | $21,101 | $N/A |
| Beginning Cash Position | N/A | 56,902 | N/A | 56,902 | N/A |
| End Cash Position | N/A | 21,252 | N/A | 40,944 | N/A |
| Net Cash Flow | $N/A | $-35,650 | $N/A | $-15,958 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | N/A | -46,639 | N/A | -37,329 | N/A |
| Capital Expenditure | N/A | -11 | N/A | -9 | N/A |
| Free Cash Flow | 0 | -46,650 | 0 | -37,338 | 0 |